Home
HelpTest Code CLLMD Chronic Lymphocytic Leukemia (CLL) Monitoring Minimal Residual Disease Detection, Flow Cytometry, Varies
Ordering Guidance
The preferred test for evaluating any tissue biopsy for a potential lymphoproliferative disorder is LLPT / Leukemia/Lymphoma Immunophenotyping, Flow Cytometry, Tissue.
The preferred test for a first-time evaluation of a patient with lymphocytosis is a routine flow cytometric assay; see LCMS / Leukemia/Lymphoma Immunophenotyping, Flow Cytometry, Varies.
Additional Testing Requirements
If cytogenetic tests are desired along with this test request, an additional specimen should be submitted. It is important that the specimen be obtained, processed, and transported according to instructions for the other required test.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube:
Preferred: Yellow top (ACD solution A or B)
Acceptable: Lavender top (EDTA)
Specimen Volume: 6 mL
Slides: If possible, include 5- to 10-unstained blood smears, must be labeled with two unique identifiers.
Collection Instructions:
1. Send whole blood specimen in original tube. Do not aliquot.
2. Label specimen as blood.
Specimen Type: Bone marrow
Container/Tube:
Preferred: Yellow top (ACD solution A or B)
Acceptable: Lavender top (EDTA)
Specimen Volume: 6 mL
Slides: If possible, include 5 to 10 unstained bone marrow aspirate smears, must be labeled with two unique identifiers.
Collection Instructions:
1. Submission of bilateral specimens is not required.
2. Send bone marrow specimen in original tube. Do not aliquot.
3. Label specimen as bone marrow.
Useful For
Confirming the presence or absence of minimal residual disease in patients with known chronic lymphocytic leukemia who are either post-chemo/immunotherapy or post-bone marrow transplant
Method Name
Immunophenotyping
Reporting Name
CLL Monitoring MRD Detection, VSpecimen Type
VariesSpecimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Ambient (preferred) | 4 days | |
| Refrigerated | 4 days |
Reject Due To
| Gross hemolysis | Reject |
| Fully clotted whole blood | Reject |
Clinical Information
Chronic lymphocytic leukemia (CLL) is a low-grade, B-cell neoplasm and is the most common leukemia detected in the western world. It is primarily associated with adult patients and may present as a lymphocytosis, be detected as part of a lymphadenopathy evaluation, or be found incidentally in an otherwise asymptomatic patient. The diagnosis of CLL is based on a combination of morphologic features showing primarily small lymphoid cells with coarse chromatin and scant cytoplasm and an immunophenotype of clonal B cells with dim immunoglobulin, dim CD20, and coexpression of CD5, CD22, CD43, and CD200.
New therapeutic approaches in CLL have been increasingly successful with some patients showing no or only very minimal residual disease (MRD) in their peripheral blood or bone marrow specimens following a therapeutic course. Immunophenotyping studies are necessary as morphologic features are not sufficient to detect MRD. The absence of MRD is an important prognostic indicator in these patients.
Reference Values
An interpretive report will be provided.
This test will be processed as a laboratory consultation. An interpretation of the immunophenotypic findings and correlation with the morphologic features will be provided by a hematopathologist for every case.
Interpretation
An interpretive report for presence or absence of minimal residual disease (MRD) for chronic lymphocytic leukemia (CLL) is provided.
Patients with CLL post treatment, who have detectable MRD by this assay, are considered to have residual CLL disease.
Cautions
This test is only appropriate for patients who have a previously confirmed diagnosis of chronic lymphocytic leukemia.
Method Description
Flow cytometric immunophenotyping (high sensitivity) of bone marrow is performed to evaluate the presence or absence of chronic lymphocytic leukemia (CLL) minimal residual disease (MRD) using the following antibodies:
CLL, MRD Panel: CD5, CD19, CD20, CD22, CD38, CD43, CD45, CD200, and kappa and lambda immunoglobulin light chains.
The sensitivity of this assay is 0.002% (2 x 10[-5]) based on 1,000,000 total events collected and an abnormal cell immunophenotype detected in a cluster of at least 20 cells. The assay sensitivity meets or exceeds the 0.01-0.001% (10[-4]-10[-5]) level of detection by flow cytometry, as recommended by the current ERIC method and NCCN guidelines for MRD analysis in CLL.(Keren P, McCoy Jr JP, Carey J, eds. Flow Cytometry in Clinical Diagnosis. 4th ed. ASCP Press; 2007; Wierda WG, Brown J, Abramson JS, et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022;20(6):622-634. doi:10.6004/jnccn.2022.0031
Day(s) Performed
Preanalytical processing: Monday through Saturday
Results reported: Monday through Friday
Report Available
1 to 4 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88184-Flow cytometry; first cell surface, cytoplasmic or nuclear marker
88185 x 9-Flow cytometry; additional cell surface, cytoplasmic or nuclear marker (each)
88188-Flow Cytometry Interpretation, 9 to 15 markers
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CLLMD | CLL Monitoring MRD Detection, V | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 608973 | CLLMD Result | No LOINC Needed |
| 608974 | Final Diagnosis | 22637-3 |
| 608975 | Special Studies | 30954-2 |
| 608976 | Microscopic Description | 22635-7 |